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Abnormal elevation of cardiac sympathetic nerve activity (cSNA) is a major contributor to the 
high mortality rate associated with acute myocardial infarction (MI). Increase in cSNA results 
in the propagation of ventricular arrhythmias, worsening the severity of damage to the heart 
and increasing the risk of sudden death. It was recently discovered that immediate 
administration of oxytocin receptor blockers (OTB) after a MI prevented increases in cSNA 
and improved survival outcomes. However, it is unknown whether the efficacy of OTBs would 
be maintained if administered at a later stage when cSNA would already be elevated. Thus, the 
purpose of this study was to investigate whether delayed administration of OTBs would allow 
for the reduction of elevated cSNA back to normal pre-infarct levels.  
CSNA was recorded pre- and post-infarct for four hours using surgical and in vivo 
electrophysiological techniques on 22 urethane-anesthetised rats. In vivo surgical procedures 
were conducted in order to obtain haemodynamic and electrophysiological data. A MI was 
induced via physical ligation of the left anterior descending coronary artery. One hour post-
infarct, a proportion of MI rats were treated with Atosiban (ATB), an OTB, to determine if 
there were any alterations to cSNA levels when compared to an untreated MI. CSNA was also 
recorded in sham rats without inducing a MI. 
All rats treated with ATB (n = 6) survived throughout the four hour recording, compared to the 
50% survival rate of untreated MI rats (n = 10). As expected, MI rats exhibited increases in 
cSNA, with a significant difference from the sham group occurring from 120 minutes (34 ± 
11%, P = 0.0417) onwards. However, the cSNA levels of ATB treated rats did not present any 
significant decreases and continued to increase over time, following a similar trend to the 
untreated MI group.  
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These findings suggest that delayed administration of ATB may not significantly reduce 
elevated cSNA levels, but could possibly lessen the overall increase in cSNA over time. Further 
investigation is needed to determine whether or not OTBs can be used as a therapeutic strategy 
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As the most common cause of death globally, the high mortality rate of an acute myocardial 
infarction (MI) can be attributed to the disproportionate increase of sympathetic activity 
following shortly after an infarct (1). Overactivation of cardiac sympathetic nerve activity 
(cSNA) results in propagation of ventricular arrhythmias associated with increased mortality, 
exacerbating cardiac damage and severity of myocardial injury (2-4). The causation for this 
sympathetic increase is still not fully understood, although, current investigations show 
indications of an emerging correlation between oxytocin (OT) release and post-infarct 
stimulation of cSNA (5-8). An initial study has determined that the immediate administration 
of oxytocin receptor blockers (OTB) in response to acute MI have identified signs of improving 
prognosis, exhibiting promising results (7). However, further insight into clinical translatability 
remains unelucidated as the optimal window of time for OTB administration remains unknown. 
Thus, this study aims to explore the applicability of delayed OT inhibition using atosiban (ATB) 
to investigate whether an OTR blockade one hour post-infarct exhibits potential as a therapeutic 
strategy to effectively reduce elevated cSNA back to pre-infarct levels. 
 
1.1. Regulation of the cardiovascular system 
Regulation of cardiac function is controlled by intrinsic and extrinsic mechanisms. Intrinsic 
regulation arises in the heart from the sinoatrial node which transmits spontaneous bursts of 
excitation potentials through the electro-cardiac pathways to stimulate contraction and 
relaxation of the heart (9). Extrinsic cardiac regulation on the other hand, is largely influenced 
by mechanisms involving endocrine and autonomic pathways (10). Endocrine regulation of the  
cardiovascular system is generally interlinked with the primary extrinsic regulator, the 




1.2. Sympathetic cardiac regulation 
As a sub-branch of the peripheral nervous system, the ANS itself has two distinct pathways 
which regulate excitatory and inhibitory signals from the central nervous system to the heart, 
known as the sympathetic and parasympathetic nervous systems, respectively (12).    
The Sympathetic nervous system (SNS) is a fundamental homeostatic regulator of normal 
cardiovascular function. associated with the fight-or-flight response, the SNS responds to 
physical changes in the body, the environment, and stress, by influencing increases in heart 
rate and blood pressure in order to maintain cardiac output (13, 14).  
 
Sympathetic cardiac innervation 
CSNA relies on afferent input from baroreceptors and chemoreceptors (15, 16). These afferent 
fibres synapse in the nucleus tractus solitarius (NTS), relaying a signal to the paraventricular 
nucleus (PVN) (17-19). Located within the hypothalamus, the PVN is comprised of 
magnocellular and parvocellular neurons which project to various neural regions involved with 
endocrine and sympathetic regulation (20). It is a distinct subpopulation of parvocellular 
neurons in the PVN that activates cSNA by projecting to sites which regulate efferent 
sympathetic signalling, either directly via the intermediolateral cell column of the spinal cord 
(IML), or indirectly from the rostral ventrolateral medulla (RVLM) which also projects to the 
IML (17, 21). Sympathetic preganglionic neurons from the IML in the superior thoracic region 
(T1-T4) synapse at the stellate ganglia to the post-ganglionic fibres which sympathetically 
innervate the heart (22) (Figure 1.1). The release of noradrenaline from the post-ganglionic 
nerve terminals allow for a sympathetic response by activating β-adrenergic receptors (β-AR) 
which generally promotes positive chronotropic and inotropic responses via their associated 
G-protein coupled receptor (GPCR) mediated pathways (23, 24). β-ARs have 3 distinct 
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subtypes known as β1, β2 and β3, with β1-ARs being expressed more prominently in cardiac 
cells than β2 in normal conditions (25). β3-AR expression, however, is associated with negative 




Figure 1.1. Schematic diagram of the cardiac sympathetic pathway. Afferent fibres project 
from the heart to the nucleus tractus solitarius (NTS), which is relayed to the paraventricular 
nucleus (PVN). The PVN can directly stimulate the intermediolateral cell column of the spinal 
cord (IML) or indirectly via the rostral ventrolateral medulla (RVLM). The IML projects 
sympathetic preganglionic fibres into the stellate ganglion (SG), synapsing with the 
postganglionic fibres in the cardiac sympathetic nerve to stimulate cardiac sympathetic nerve 




Parasympathetic cardiac innervation 
The parasympathetic nervous system mediates negative chronotropic, dromotropic and 
inotropic effects on cardiac function (26). Activation of this pathway is initiated by the dorsal 
vagal nucleus (DVN) and nucleus ambiguus which both project down the vagus nerve (27, 28). 
These parasympathetic preganglionic fibres synapse at the cardiac ganglia where 
postganglionic fibres emerge, stimulating a parasympathetic response (27) (Figure 1.2). 
 
 
Figure 1.2. Schematic diagram of cardiac parasympathetic innervation. Diagram depicts 
the dorsal vagal nucleus (DVN), also referred to as the dorsal motor nucleus, and the nucleus 
ambiguus projecting down the vagus nerve/ganglion, synapsing at the cardiac ganglia where 
the postganglionic fibres emerge to innervate the heart. Image adapted from Rajendran et al., 





1.3. Acute myocardial infarction 
 
Figure 1.3. Diagram of an infarcted heart and thrombotic occlusion of the left anterior 
descending coronary artery. Diagram illustrates how accumulation of plaque around the 
arterial lumen obstructs the passage of red blood cells to the heart. Loke 2020, original work. 
 
The cardiovascular system regulates essential delivery of oxygen and nutrients to the various 
organs and tissues of the body, including the heart itself (29). Coronary artery disease (CAD) 
exhibits the highest prevalence in mortality rates world-wide, attributing to approximately 85% 
of all cardiovascular related deaths (30). CAD is typically caused by accumulation of 
atherosclerotic plaque in the walls of the coronary arteries which narrows the vessel, resulting 
in decreased blood circulation (31, 32). Over time, plaque instability elicits erosion or rupture 
of the fibrous cap, exposing the plaque to the lumen which instigates platelet aggregation and 
clotting resulting in development of a thrombus and consequential obstruction of essential 
circulation to cardiac tissue (31, 33) (Figure 1.3). As the heart requires a constant supply of 
blood in order to allow for normal cardiac function, the inability to receive oxygen to supply 
cardiac tissue creates a hypoxic environment where the heart can no longer maintain 
cardiomyocyte viability (34). As a consequence, an acute MI is initiated, invoking pathological 
myocardial modifications such as: 
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• Elevation of reactive oxygen species (ROS) levels and oxidative stress which adversely 
affects mitochondrial function and energy synthesis (35). 
• Autophagy, apoptosis and recruitment of inflammatory cytokines in response to 
increased ROS and damaged cardiomyocytes (36).  
• Increased cellular Ca2+ influx and increased acidity levels from lactate production due 
to the conversion to anaerobic glycolysis, a non-oxygen energy synthesis pathway to 
compensate for reduced energy production (37). 
 
The effects of acute myocardial infarction 
In response to the pathological changes occurring due to a MI, the heart sends afferent distress 
signals to the CNS which elicits an increase in cSNA (38). The stimulation of cSNA is 
comparatively faster and larger compared to the activation of other sympathetic sites in the 
body when responding to an MI (2), increasing within an hour of the infarct and reaching 
maximal levels at the second and third hour, resulting in sustained elevation over a duration of 
days to months (39, 40). The elevation in cSNA is caused by stimulation of superior thoracic 
SPNs in response to the myocardial modifications associated with acute MI, leading to a 
considerable increase in cardiac noradrenaline (NA) levels and therefore increased sympathetic 
tone (38, 41).  
The increase in cSNA results in arrhythmogenesis which occurs in the first hour after the onset 
of an MI, increasing the risk of tachy-arrhythmic incidences and therefore sudden cardiac death 
as arrhythmias weaken ventricular ejection due to an irregular increased heart rate caused by 
cardio-electrical misfiring, thus resulting in impaired cardiovascular circulation (4, 42).  
At the site of the infarct, affected cardiomyocytes begin to necrotise, accompanied by acute 
inflammation (43). The intrusion of macrophages in response to necrosis enhances the 
progression of intracellular oedema, resulting in swelling of cardiac tissue (43).  
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Cardiac remodelling manifests throughout the first few weeks after the infarct, expressed by 
the thinning of ventricular walls due to cell loss and rearrangement of subendocardial muscle 
fibres, distorting the morphology of the heart (44). Afferent cardiac fibres are also affected, 
leading to impaired signal transduction and desensitised responses to neural input depending 
on the region of cardiac tissue affected (45).  
 
1.4. Current therapeutic strategies: 
There are a range of therapeutic strategies involving medications to treat the effects associated 
with acute MI and surgical procedures that aim to restore blood flow and remove coronary 
obstructions, in which both have greatly improved patient prognosis. Currently, the gold-
standards in treatment of acute MI are β-blockers and reperfusion therapy. β-blockers act non-
specifically on the β-ARs by improving ventricular function through negative inotropic and 
chronotropic effects (46). Despite the benefits of β-blockers, The eligibility criteria for access 
to this treatment strategy is suggested to be relatively high due to contraindications which 
prevents subpopulations like the elderly from receiving appropriate treatment (47). 
Reperfusion therapy has also showed promising results in reducing occlusion of the affected 
artery, preventing further cardiac deterioration by reducing infarct size and sustaining 
ventricular function (48). Yet, achieving a better prognosis is highly time dependent, with the 
rate of treatment effectiveness decreasing rapidly within the first 30 minutes to 4 hours after 
the onset of an infarct (49).  
As of now, effective and viable therapeutic strategies targeting the initial adverse increase of 
cSNA following an MI have not yet been identified and remains an area of active research. 
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1.5. Oxytocin and autonomic regulation 
Oxytocin is widely established for its role as a hormone involved with parturition and milk 
ejection, yet what is lesser known is OT’s association with the ANS, specifically, the 
cardiovascular system (50-52). OT release originates in the PVN as well as the supraoptic 
nucleus (SON) (52). Processes involving the posterior pituitary gland, and therefore release of 
OT into the vascular system to stimulate parturition and milk ejection are regulated by 
magnocellular OT neurons found in the PVN and the SON (50, 52). Although the parvocellular 
division of the PVN is already strongly associated with autonomic and neuroendocrine control 
of cardiovascular function (53, 54), a distinct subset of OT-expressing parvocellular neurons 
located in the PVN was also found to project to the RVLM and its associated sympathetic 
pathways (55, 56) (Figure 1.4).  
 
 
Figure 1.4. Flowchart of the oxytocinergic pathway from the PVN. Diagram illustrates the 
pathways of the magnocellular and parvocellular OT neurons from the paraventricular nucleus 




1.6. The oxytocin receptor 
Oxytocin receptors (OTR) are recognised as class-A GPCRS, belonging to the same family as 
β-ARs (23, 57). In typical cases of OT stimulation, OT binds to the Gq subtype of the GPCR 
family in order to induce contraction while stimulating the release of Ca2+ from intracellular 
stores (58). In association with cardiac regulation, OTRs have also been located in the cardiac 
regions, such as the aorta, atrioventricular sites and vena cavae (59).  
 
Oxytocin receptor blockers 
OTBs such as atosiban (ATB) have been found to eradicate the adverse increase in cSNA 
following a MI (7). ATB is a competitive, reversible OTR antagonist with promising safety 
profiles (60). Currently in phase III clinical trials, ATB has been treated on pregnant women 
as a pre-term labour preventative strategy, showing effective results in reducing uterine 
contractions as well as reducing oxidative stress (61). Furthermore, ATB has been found to 
have no negative effects on cardiovascular function (62).    
 
1.7. Oxytocinergic cardiac sympathetic innervation:  
OT innervation in response to ‘distress’ signals such as physical pain or injury has been shown 
to trigger cSNA, provoking increases in heart rate (6, 63, 64). Additionally, from a 
neurochemical standpoint, in response to these ‘distress’ signals, increase in cSNA was 
identified alongside a seven-fold increase in OT from basal levels in the PVN (63).   
In regards to the cSNA pathway, it was found that 79% of neurons projecting from the 
parvocellular PVN neurons to the RVLM were oxytocinergic as well as 38% of neurons from 
the PVN that projected directly to the IML (21). OT-expressing neuronal fibres at the IML 
have also exhibited the ability to directly innervate large numbers of superior thoracic SPNs to 
elicit a sympathetic response (56, 65). 
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1.8. Oxytocin’s involvement in acute myocardial infarction: 
OT activation is a relatively unexplored aspect of the mechanisms associated with acute MI. 
New research has found that in response to acute MI, parvocellular OT neurons from the PVN 
projecting to the RVLM are activated (7). Increased levels of OT and upregulation of OTRs 
have also been detected in the sympathetic cervical ganglia and heart alongside a post-infarct 
increase in cSNA (8, 59), while an immediate blockade of OTRs after an acute MI entirely 
prevented the pathological MI-associated increase in cSNA (7). 
Furthermore, it is suggested that the pathological overexpression of cardiac OTRs may be 
involved with the associated adverse cardiac modifications exhibited in an acute MI such as 
increased intracellular Ca2+ levels, detrimental cardio-hypertrophic effects as well as apoptosis 
of cardiomyocytes through various GqPCR-associated signalling pathways (5, 66, 67).  
 
1.9. Oxytocin receptor blockade as a therapeutic strategy for acute MI 
To date, there is only one study which explores the use of OTBs as a therapeutic strategy for 
acute MI, to which they discovered that immediate administration of OTBs such as retosiban 
and ATB  after an MI was able to lead to the abolishment of the adverse increase in cSNA (7), 
thus being the first study to discover the potential of OTBs as a therapeutic strategy for acute 
MI. However, although it is known that immediate OTB treatment is effective in preventing 
cSNA increases, the impossibility of immediate treatment limits the clinical translatability of 
OTBs. Therefore, it is imperative to investigate the therapeutic window of opportunity 
associated with OTB efficacy. As such, this study may be the first to examine the possibility 




1.10. Aims and hypothesis 
This study intends to further explore the relationship between OT and the MI-associated cSNA 
increase as well as the clinical applicability of oxytocin receptor blockers. This will be 
conducted through investigation of whether a delayed 1 hour administration of ATB post-MI 
can effectively reduce elevated cSNA back to pre-infarct levels.  
A 1 hour delay before administration allows for a conceptual test of viability for real-world 
application as a potential primary response strategy in reducing mortality risk. Thus, as OTBs 
have indicated therapeutic potential in the regulation of MI-associated cSNA, I hypothesised 
that it was possible to reduce the post-infarct associated increase in cSNA and expected to see 




2. MATERIALS & METHODS 
2.1. Animals 
All experiments were approved and conducted in accordance with the guidelines supplied by 
the University of Otago Animal Ethics Committee, New Zealand. Experiments were conducted 
on 6 – 8 week old male Sprague Dawley rats (350 – 500g). 22 rats were allocated into 3 groups; 
Sham (n = 6), MI (n = 10), or MI + ATB (n = 6) and were housed in a temperature regulated 
environment (25˚C ± 1˚C) on a 12 hour light/dark cycle with ad libitum access to food (standard 
laboratory chow) and water. 
 
2.2. Non-recovery surgical procedures: 
Surgical anaesthesia 
Rats were deeply anaesthetized via intraperitoneal injection of urethane (1.5g/kg; Sigma-
Aldrich®, St Louis, MO, USA). Full anaesthesia was confirmed by complete loss of limb 
withdrawal reflex in response to a firm toe pinch.  The neck, left axilla and chest, left groin and 
head were shaved once under full anaesthesia.  
 
Intracerebroventricular (ICV) surgery  
A stereotaxic ear bar was secured on both sides of the skull at the ear cavity before the rat was 
fitted on a stereotaxic frame. Once secure, an incision was made at the midline of the scalp, 
starting at the base of the ears towards the eyes (Figure 2.1). The subcutaneous connective 
tissue adhering to the skull was removed to reveal the bregma, the site of intersection between 
the sagittal and coronal sutures. Once the bregma was identified, a 22 gauge guide cannula 
(C313G-SPC, Bio-Scientific Pty. Ltd) was positioned and adjusted to locate the right lateral 
cerebral ventricle (RLCV) using coordinates from Paxinos & Watson (0.8mm posterior to 
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bregma, 1.5mm lateral to midline) (68). Using a drill (LEC-800, Nihon Seimitsu Co., Ltd), a 
2mm diameter hole was made at the guide point. An additional 1mm hole was made to install 
a micro screw (specifications: M1.0 x 3mm) to provide scaffolding support as the cannula was 
inserted into position. The surgical site was then covered with dental cement to prevent 
displacement of the cannula. Once the dental cement had solidified, the animal was removed 
from the stereotaxic frame and placed onto a surgical board while a needle tipped catheter filled 
with either 10µL of atosiban (10µg/10µL, Sigma CAS Number 90779-69-4) or saline was 
inserted into the cannula. Confirmation of drug delivery was visualised at the end of each 
experiment via injection of 5µL of Evans blue dye through the cannula (Figure 2.2). 
                                       
	
Figure 2.1. Outline of ICV surgical procedure. (A) A midline incision on the scalp, spanning 
from the ears towards the eyes. (B) Separation of connective tissue adhering to the skull via 
scalpel. (C) Haemostats used to retract scalp. (D) identification the bregma. (E) Identified 
location of RLCV, marked with pencil. (F) Drilled hole at RLCV on the right, with an 
additional hole drilled on the left for insertion of a screw. (G) Installation of cannula and screw. 





Figure 2.2. Evans blue stain on brain slice. Image depicts successful placement of cannula 
as seen by the infiltration of Evans blue in the ventricles of the brain (areas of blue 




Placement of animal for surgery 
Upon completion of  ICV surgery, the rat was transferred and placed in supine position on a 
heating pad (Figure 2.3). Body temperature was maintained at 37˚C using a rectal thermistor 
connected to a thermostatically controlled heating pad (BWT-100, Bio Research Centre Co., 
Ltd). 
 
Figure 2.3. Schematic diagram of surgical set up. Image shows rat secured on the surgical 
board with rectal thermistor and heating pad. Shaded regions are used to visualise locations 





A 15mm midline incision was made at the base of the jaw towards the sternum (Figure 2.4). 
Visceral fat was excised to reveal the sternohyoid muscle which was blunt-dissected to access 
and isolate the trachea.  Ligatures were tied loosely around the caudal and rostral regions of 
the trachea and a small incision was made anteriorly, allowing for insertion of a polyethylene 
tracheal cannula (1.7mm ID, 2.7mm OD). The cannula was positioned caudally to ~10mm and 
was held in place by tightening the caudal and rostral ligatures. The cannula was then attached 
to a rodent ventilator (M-7025, UGO Basile, Italy) to maintain normocapnic arterial PCO2. 
Ventilator settings were adjusted according to the body weight of the rat (respiration rate: ~80 




Figure 2.4. Outline of tracheostomy procedure. (A) Midline incision exposing subcutaneous 
fat. Caudal and rostral labels indicate positioning of rat. (B) Visualisation of sternohyoid 
muscles (outlined in blue), light blue line indicates site of blunt dissection to expose trachea. 
(C) Isolation of trachea. (D) Positioning of ligatures. (E) Radial incision of trachea (blue arrow). 





Catheterization of the femoral artery and vein: 
A skin incision originating 3cm above the medial malleolus of the left hindlimb was made. Via 
blunt dissection, skin was separated from the subcutaneous fat pad and connective tissue before 
the initial incision was extended towards the midline (Figure 2.5). The subcutaneous fat was 
electro-cauterized (Geiger Medical Technologies-150A, USA) to reveal the femoral artery and 
vein underneath. Using a stereo microscope (Leica M80, Germany), the femoral artery and 
vein were isolated from the surrounding connective tissues using blunt-tip tweezers and curved 
forceps.  
Once the vessels were isolated, two pieces of surgical suture (4/0 silk USP, Resorba, Germany) 
were threaded underneath the femoral artery and positioned proximally and distally. The suture 
positioned at the distal region was firmly ligated. A microvascular clamp was placed above the 
proximal thread to prevent blood flow and the proximal suture was loosely tied. Using iris 
scissors, a small radial incision was made between the proximal and distal sutures, allowing 
for the insertion of an arterial catheter into the lumen of the artery which was advanced beyond 
the vascular clamp and inguinal ligament. The arterial catheter was connected to a deltran 
pressure transducer (Utah Medical Products Inc., Utah, USA) in order to monitor arterial blood 
pressure (ABP), and was filled prior to catheterisation with heparinised saline (40 I.U./mL, of 
0.9% NaCl) to prevent coagulation of blood within the catheter.  
The same process was repeated for the catheterization of the femoral vein, with the insertion 
of a saline-filled (0.9% NaCl) catheter connected to an electronic perfusion pump (PhD UltraTM, 
Harvard Apparatus, Holliston, MA) to maintain hydration levels in the animal via constant 




Figure 2.5. Outline of femoral artery catheterisation procedure. (A) incision on left 
hindlimb exposing subcutaneous fat pad. (B) Visualisation of femoral vessels below fat pad. 
(C) Retractors positioned to provide further exposure of femoral vessels. (D) Isolated femoral 
vein and artery. Inguinal ligament (IL) is clearly visualised. (E) Distal ligature knotted. (F) 
microvascular clamp and loosely knotted proximal ligature in position. Incision made between 
ligatures, closest to distal ligature as seen by white arrow. (G) insertion of arterial catheter. (H) 
Proximal ligature tightened to secure catheter. (I) Catheter advanced up artery and proximal 




A skin incision was made down the midline above the sternum and toward the xiphoid process 
(Figure 2.6). To further expose the thoracic musculature, an incision was made perpendicular 
to the midline, from the xiphoid process to the left mid-axillary line. The skin flap was laterally 
reflected prior to removal of muscles found at the surgical site (pectoralis major and minor, 
rectus abdominis, and external oblique), via blunt dissection and electrocautery to prevent 
haemorrhage (Geiger Medical Technologies-150A, USA).  
Two small incisions were made near the sternal border, one at the 2nd intercostal space and the 
other at the 3rd intercostal space on both sides of the 3rd rib. A ligature was pulled through these 
incisions using blunt-tip curved forceps. Further incisions were made towards the left mid-
axillary line of the 3rd rib where the 2nd ligature was positioned. Prior to excision of ribs using 
a rib-cutter, the ligatures were both tightened and double-knotted to prevent blood loss from 
intercostal vessels, This procedure was repeated on the 2nd rib and 4th rib. All ligatures were 
pulled away from the body and taped to the surgical board so as to further open up the exposed 




Figure 2.6. Left thoracotomy procedure. (A) midline incision exposing thoracic region. (B) 
Lateral reflection of skin flap. (C) Removal of Pectoralis major (PM) (dotted blue line indicates 
location of muscle), pectoralis minor is not shown in image, but was also removed. (D) removal 
of rectus abdominis (RA) from thoracic region. (E) Removal of external oblique (EO). (F) 
Insertion of curve forceps in area of incision for ligation. (G) Ligatures threaded through 
incisions. Numbers indicate rib arrangement of rat to be removed. (H) Ligatures in position 
and secured. Rib isolated and ready for removal. (I) Removed 3rd rib. (J) Removed 4th and 
2nd rib. Ligatures positioned to expose thoracic cavity. 
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Ligation of left anterior descending coronary artery: 
The pericardium was removed via blunt dissection to allow for access to the left anterior 
descending (LAD) coronary artery. The LAD coronary artery was located descending from the 
left coronary artery (or in cases where the left coronary artery is not visible, directly from the 
left aortic sinus) through the interventricular groove towards the apex of the heart (69). A 6/0 
Prolene suture (Ethicon Inc., USA) was threaded around the LAD coronary artery by passing 
the thread from the base of the pulmonary conus, beneath the left atrium, passing next to the 
right wall of the left atrial appendage (70). The suture was loosely tied in a triple knot. To 
induce an infarct, the ligatures were tightened and tied again to prevent loosening. Successful 
ligation resulted in discolouration of the left ventricle (Figure 2.7). 
 
 
Figure 2.7. Successful ligation of the left anterior descending (LAD) coronary artery. 
Suture is tied around the LAD coronary artery. Discolouration can be seen near the apex of the 
heart (light blue arrow).  
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Cardiac sympathetic nerve isolation: 
Using a cotton swab and fine tooth tweezers, fat and connective tissue at the region of the 1st 
and 2nd ribs were meticulously cleared to expose the stellate ganglion and cardiac sympathetic 
nerve (CSN) (Figure 2.8). The CSN was identified and was carefully isolated with minimal 
stretching and contact to prevent nerve damage. Once isolated, a fine ligature (6/0 silk USP, 
Resorba, Germany) was threaded under the nerve using fine curved forceps and tied at the 
region of the nerve most visibly distal to the stellate ganglion. The region of the nerve distal to 
the ligature and was cut with micro-scissors and carefully placed on a platinum recording 
electrode. To prevent desiccation of the nerve, the nerve was enveloped with paraffin oil.  
 
 





Recording of sympathetic activity: 
Sympathetic activity was recorded 10 minutes before and 4 hours after the induction of a MI. 
Via bio-amplifier (BMA-200, AC/DC Bioamplifier, USA), noise interference was filtered and 
raw sympathetic activity was amplified. To confirm the presence of sympathetic activity, a 
speaker connected to the bio-amplifier allowed for audible detection of spikes of activity, 
characterised by irregular beats. The altered signal from the bio-amplifier was connected to an 
oscilloscope, allowing for visible real-time identification of sympathetic excitation potentials. 
An amplitude discriminator (WD-2 Time-Amplitude Window Discriminator, Dagan Corp., 
Minneapolis, MN) was used to distinguish between noise interference and genuine sympathetic 




2.3. Experimental Protocol  
Rats were randomly assigned into one of three groups, 1) Sham, 2) MI, or 3) MI + ATB. All 
rats underwent surgical preparation to allow for electrophysiological and haemodynamic data 
collection. Once cSNA stabilised, baseline data was recorded 10 minutes prior to coronary 
occlusion (MI and MI + ATB group only), and was continuously recorded for four hours after 
(Figure 2.9). The MI + ATB group were centrally administered with 10µL of ATB (10µg/mL) 
one hour after the induction of an MI. At the end of the four hour recording, rats were 
terminated with 0.5mL of KCl. The brain was injected with 5µL of Evans blue for confirmation 
of administration in ATB treated rats. Hearts subjected to MI were extracted and stained for 
infarct size analysis. 
 
 
Figure 2.9. Experimental protocol timeline. After surgery, baseline recordings of 
haemodynamic and electrophysiological data were collected from all three groups (Sham, MI, 
MI + ATB), to which 10 minutes later at ‘0 hours’, MIs (MI; myocardial infarction) were 
induced in the MI and MI + ATB group. ATB (atosiban) was administered 1 hour later in the 
MI + ATB group. At 4 hours, rats which survived for the entire protocol were terminated. 




2.4. Data collection and statistical analysis 
Equipment set-up: 
Before initiation of the recording protocol, ABP was recorded via a deltran pressure transducer 
(Utah Medical Products Inc., Utah, USA), sampled at 400Hz and amplified via bridge amplifier 
(MacLab, AD Instruments). The amplified signal was then sent to an 8-channel PowerLab data 
acquisition system (PowerLab 8/35, AD Instrument Pty Ltd, Australia) connected to a 
Macintosh desktop running ‘LabChart Pro’ recording software (AD Instrument Pty Ltd, 
Australia 1986-213). Heart rate (HR) was then generated from the ABP channel via computed 
input from Labchart. 
The channel recording for cSNA was calibrated against a 100µV signal produced by the bio-
amplifier (BMA-200. AC/DC Bioamplifier, USA). This 100µV signal was used for two-point 
calibration (0µV and 100µV), allowing for accurate assessment of sympathetic activity. This 
raw sympathetic signal was then subsequently used to generate an integrated cSNA signal. The 
actual value of the integrated signal was determined by subtracting the background noise value 
at the end of the recording protocol.  
 
Statistical analysis 
Data was collected 5 minutes before (-5) and during coronary occlusion (0) and at time points 
5, 10, 20, 30, 60, 75, 90, 120, 180 and 240 minutes post infarct which was consequently 
organised on Excel (Microsoft, 2010). Arrhythmic episodes were calculated in hourly intervals 
(0-1, 1-2, 2-3 and 3-4). Data collected from cSNA was normalised to percentage changes from 
baseline using the equation  !"#$%&"'!()*+$,"'$)*+$,"'$ . Means and SEMs were generated using excel 
for individual timepoints in all groups for cSNA, ABP, HR and arrhythmias which were then 
analysed on Prism (GraphPad software 7.0, San Diego, CA, USA). Via one-way analysis of 
variance (ANOVA) tests, differences in timepoints were identified. Statistically significant 
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differences were then compared to baseline via Dunnett’s post hoc test and between timepoints 
via Bonferroni post hoc test. Individual time points between sham and MI, as well as MI and 
MI + ATB were compared via 2-way ANOVA, with significant differences analysed via 
Bonferroni post hoc test. Differences in infarct size was analysed via unpaired t-test. Kaplan-
Meier survival analysis was conducted to identify the survival curves between all three groups. 
A P value of  ≤0.05 was considered statistically significant. 
 
 
2.5. Infarct size analysis 
2,3,5 Triphenyl tetrazolium chloride staining: 
At the completion of the SNA recording procedure, rats were euthanised with 0.5mL of KCl. 
Once sympathetic activity was no longer detected, the background noise value was obtained 
for subtraction from the integrated sympathetic signal. Hearts were immediately extracted and 
submerged with ice-cold phosphate buffered saline (1% PBS) solution. To flush interior of the 
heart, a cannula attached to a PBS filled 10mL syringe was inserted into the aorta and secured 
using a piece of thread (4/0 silk USP, Resorba, Germany) and then slowly infused into the heart. 
Once the effluent no longer contained traces of blood, the heart was perfused with 50mL of 
37˚C 2,3,5-triphenyl tetrazolium chloride (TTC) (Sigma-Aldrich®, St Louis, MO) solution via 
perfusion pump for 15-20 minutes at 0.5mL/gm/min (Figure 2.10). 
After the TTC perfusion, hearts were placed in a freezer (-20 degrees) for approximately 20 
minutes. Hearts were then placed in a rodent heart matrix (Zivic Instruments, Pittsburgh, PA) 
and sliced transversely into uniform 3mm sections. The hearts were sandwiched between two 
Perspex panels and tightened with screws to ensure a uniform thickness of 2mm in all slices 




Figure 2.10. Staining of heart with 2,3,5-triphenyl tetrazolium chloride (TTC). (A) Heart 
is perfused with TTC. Infarcted areas are stained white while non-infarcted areas are stained 
red. (B) transverse cross-section of the heart. Infarcted areas are identified (dotted green area) 
and compared with the overall area of the left ventricle (purple line). 
 
Quantification of infarct size: 
Quantification of infarct size was conducted using ImageJ software (version 1.53a, NIH). The 
total areas of the left ventricle (including atrioventricular septum), ventricular lumen and 
infarcted zone were calculated. The area of the ventricular lumen was subtracted from the area 
of the left ventricle to determine the actual left ventricular area. Then, the proportion of area of 






3.1. Baseline data 
Before the induction of a MI, baseline electrophysiological and haemodynamic data were 
collected and quantified (Table 3.1). No significant differences were observed pre-MI at 
baseline between the sham, MI and MI + ATB groups in all of the variables.  
 
Table 3.1. Baseline electrophysiological and haemodynamic parameters. Data is presented 
as mean ± SEM. Data for absolute integrated cardiac sympathetic nerve activity (cSNA), mean 
arterial blood pressure (MABP), heart rate (HR) and total body weight was collected from sham 
(n = 6), MI (n = 7) and MI + ATB (n = 6) groups. The P-value was calculated from all 3 groups 
via one-way ANOVA. There were no significant difference between any of the groups for each 
variable. 
 Sham (n = 6) 
MI 
(n = 7) 
MI + ATB 
(n = 6) P value 
Integrated cSNA (µV.s) 4.52 ± 1.03 4.23 ± 0.98 2.02 ± 0.71 0.1472 
MABP (mmHg) 72 ± 6 87 ± 5 77 ± 3 0.1134 
HR (bpm) 403 ± 12 372 ± 21 376 ± 11 0.4773 





Of the 10 rats in the MI group,  five rats died during the four hour recording protocol, exhibiting 
a 50% survival rate at 240 minutes (Figure 3.1) Intriguingly, all six MI + ATB rats survived 
for the entire duration of the experimental protocol (100% survival).  
Further analysis of electrophysiological and haemodynamic changes in the MI group were 
analysed using data from seven rats, including those that died before four hours, by using the 
data collected until their time point of death. Two rats died in less than 30 minutes, which was 
attributed to sudden cardiac death due to cardiac arrythmias. Rats that died from blood loss or 
hypotension were conclusively excluded from this experiment. 
 
 
Figure 3.1. Kaplan-meier survival curves depicting survival rates of sham (n=6), MI 
(n=10) and MI + ATB (n=6) groups over the duration of 4 hours. MI + ATB and sham 
exhibited no change in survival rate (100% survival) in comparison to the 50% survival rate of 
the MI group at 4 hours. Dotted line represents time of ATB injection in the MI + ATB group. 
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3.3.  Arrhythmic episodes  
Arrhythmic episodes associated with acute MI were identified and quantified into hourly 
intervals to observe changes in incidence over time. Arrhythmias were exhibited in MI and MI 
+ ATB groups upon induction of an acute MI and were identified via irregular changes in blood 
pressure, seen as a succession of ectopic beats which occur between sets of normal cardiac 
activity (Figure 3.2). Arrhythmias were most commonly seen in the first hour post-infarct, 
with a significant decrease from 29 ± 7 to 1 ± 1 episodes after the first hour in the MI group (n 
= 7, P < 0.0001; Figure 3.3). The MI + ATB group also exhibited a significant decrease from 
35 ± 12 in the first hour to 3 ± 2 episodes in the 1st to 2nd hour (n = 6, P = 0.0073). In both 
groups, the incidence of arrhythmias in the 2nd to 3rd hour continued to decrease, however were 
not significantly different to that of the 1st to 2nd hour. No arrhythmias were detected in the 3rd 




Figure 3.2. Typical Labchart trace depicting arrhythmic episodes between periods of normal cardiac beats following acute myocardial 
infarction. Arrhythmic episodes are visualised as irregular fluctuations of blood pressure (blue boxes). MABP; mean arterial blood pressure, HR; 




Figure 3.3.  Arrhythmic episodes in hourly intervals.   Arrhythmias in the MI group 
significantly reduced after the 1st hour (n = 7, one-way ANOVA with Dunnett’s post hoc test;  
****P < 0.0001). Similarly, the MI + ATB group also exhibited a significant decrease in 




3.4.  Infarct size analysis 
The proportion of necrotic tissue created as a result of the MI (i.e. infarct size) was identified 
via TTC staining, to which the area of infarcted tissue was quantified to determine the severity 
of the infarct (Figure 3.4). Animals in the MI group that did not survive past 30 minutes upon 
onset of a MI were excluded from infarct size analysis as TTC staining could only accurately 
detect necrotic damage after ~30 minutes of ischemia.  
The MI + ATB group had a mean infarct size of 36 ± 4% (n = 6) which was significantly larger 
compared to the MI group which had a mean infarct size of 23 ± 1% (n = 7). Infarct sizes 
between groups was found to be significantly different (P = 0.0051). 
 
Figure 3.4. Infarct sizes of MI and MI + ATB groups. Infarct size is expressed in percentages 
as a proportion of the total left ventricle. MI + ATB (n = 6) was found to have a significantly 
larger infarct size (36 ± 4%) compared to that of the MI group (23 ± 1%, n = 7, unpaired t-test; 
**P = 0.0051) 
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3.5. CSNA response to acute myocardial infarction and atosiban 
Sham cSNA remained stable and similar to baseline for all 4 hours with no significant changes 
between time points.  
In the MI group, cSNA began to increase at 30 minutes post infarct, but exhibited a significant 
increase  at 180 minutes (49 ± 14%, P = 0.0032) and 240 minutes (79 ± 21%, P =0.0001) when 
compared to baseline (Figure 3.5). When compared to the sham group at similar time points, 
a significant difference between groups was observed at 120 minutes (P = 0.0417), 180 minutes 
(P = 0.0069), and at 240 minutes (P < 0.0001).  
Similar to the MI group, the MI + ATB group displayed significantly elevated cSNA levels at 
180 minutes (61 ± 21%, P = 0.0497) and 240 minutes (90 ± 35%, P = 0.0007) when compared 
to baseline. When comparing percentage increases in cSNA between MI and MI + ATB, no 
significant differences were identified. Overall, the MI + ATB group exhibited a increase in 





Figure 3.5. Percentage change in cardiac sympathetic activity over time following acute 
MI or sham. MI rats were either untreated (MI; n = 7) or treated with ATB (MI + ATB; n = 
6). The MI group shows a significant increase from baseline at 180 minutes (**P = 0.0032) 
and at 240 minutes (****P = 0.0001). When compared to sham (n=6),  significant differences 
between MI and sham were observed at 120 minutes († P = 0.0417), 180 minutes († P = 0.0069), 
and at 240 minutes († P < 0.0001). MI + ATB exhibits a significant increase from baseline at 
180 minutes (61 ± 21%, *P = 0.0497) and 240 minutes (90 ± 35%, ***P = 0.0007). Dotted line 
indicates time of ATB (atosiban) administration in the MI + ATB group.  
* indicates significant difference from baseline (one-way ANOVA with Dunnett’s post-hoc 
test; P < 0.05). † indicates significant difference to sham (2-way ANOVA with Bonferroni’s 
post-hoc test; P < 0.05). 
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3.6.  Haemodynamic responses to acute MI and atosiban 
As expected, the haemodynamic data for the sham group remained stable for all four hours of 
recording with no significant changes over time. No significant changes in mean arterial blood 
pressure (MABP) was observed between groups (Figure 3.6a). Heart rate remained stable in 
all three groups for the entire four hour protocol with no significant differences observed 




Figure 3.6. Changes in haemodynamic parameters following acute myocardial infarction 
or sham. (A) Graph depicts mean arterial blood pressure (MABP) between groups. No 
significant differences were observed between  sham (n = 6), MI (n = 7), and MI + ATB (n = 
6). (B) Comparison of heart rate (HR) parameters between groups. No significant changes were 
found between groups and between time points. Dotted line indicates time of ATB (atosiban) 





This study aimed to assess the efficacy of ATB on elevated cSNA one hour following the onset 
of an acute myocardial infarction. Direct electrophysiological nerve recordings showed an 
expected increase in cSNA following coronary occlusion that consistently elevated over time. 
Administration of ATB one hour after coronary occlusion did not exhibit a reduction in cSNA 
and instead continued to rise over time, following a similar progression to that of an untreated 
MI. However, due to differences in infarct size between groups, it was not possible to 
comprehensively establish whether the lack of response in cSNA to ATB was due to a decrease 
in efficacy in ATB due to delayed administration, or as a result of the MI group expressing 
cSNA levels that are lower than what is usually observed in literature. Haemodynamic factors 
such as MABP and HR remained largely stable throughout the recording protocol.  
 
4.1. Mortality 
As the leading cause of death globally, a significant factor contributing to the high mortality 
rate associated with acute MI is the elevation in cSNA, which is known to drive the generation 
of potentially-fatal arrhythmias shortly following the onset of an infarct (1). In this study, rats 
in the MI group displayed a 50% mortality rate in the four hours following MI induction, which 
concurs with that previously reported in literature (7, 40, 71). Intriguingly, in MI rats that were 
treated with the oxytocin receptor blocker, ATB, there was 100% survival in the four hours 
post MI.  
Identification of infarct size has long been employed as a prognostic determinant of outcomes 
associated with acute MI, with infarct size correlating to the extent of impaired left ventricular 
function and mortality (71-74). In this study, the infarct size of the MI group (23 ± 1%) was 
considerably lower than the ~40% infarct size  consistently reported in previous related studies  
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(7, 40, 72). Moreover there is little observed variation in haemodynamic parameters and left 
ventricular function compared to a normal functioning heart if the infarct size is found to be 
less than 30% (71). Hence, given the significant difference in infarct size between untreated 
MI rats (23%) and MI+ATB rats (36 ± 4%)  in our current study, it is not possible to make 
definitive and conclusive comparisons regarding the effect of delayed ATB administration on 
the magnitude of sympathetic activation. In recognition of this weakness, however, I do note 
that the MI + ATB group still exhibited a 100% survival rate despite the larger infarct size and 
associated mortality risk compared to the untreated MI group. 
The mechanisms underpinning arrhythmogenesis is multifactorial, of which increased cSNA 
is known to strongly influence the risk of sudden cardiac death (2-4). Despite the obvious 
difference in infarct size between MI groups, Arrhythmias were observed, mostly within the 
first hour, in both MI and MI + ATB groups with similar incidence rates. All recorded deaths 
were attributed to arrhythmia-induced sudden cardiac failure.  
 
4.2. Sympathetic responses to MI  
Upon onset of an acute MI, elevation of cSNA occurs within an hour post-infarct, with the rise 
in cSNA reaching maximal levels within 2-3 hours (39). This elevation in cSNA has been found 
to be sustained over time for as long as 6 months after the MI (75). As mentioned previously, 
cSNA is closely associated with arrhythmogenesis and sudden cardiac death, emphasising the 
detrimental effects associated with the pathological stimulation of cSNA. 
Here, this study reported a 78 ± 21% increase in  cSNA following acute MI, which is 
considerably lower than that reported in previous studies conducted on anaesthetised rat models 
which exhibit increases in cSNA ranging from 110%-190% (7, 40). The reason for this 
moderate overall increase in cSNA can possibly be attributed to the smaller infarct size of the 
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MI group, which was lacking the capacity to trigger a large increase in cSNA. Remarkably, 
there is no study that has directly correlated infarct size with the magnitude of sympathetic 
activation and, thus, remains an area of research that warrants further investigation.  
Additionally, the location of OT expressing neurons in regions of sympathetic regulation, and 
its stimulation of cSNA increase in response to acute MI remains an area of active research in 
further understanding the mechanisms involved in MI-associated cSNA as well as the potential 
treatment strategies for cSNA regulation.  
 
4.3. The effect of Atosiban on elevated cSNA 
ATB is a competitive OTR antagonist with a promising safety profile commonly used in 
treatment for women experiencing pre-term labour (60, 62). Although ATB has been found to 
have no side effects on the cardiovascular system in pregnant women (58), information 
regarding the effects of ATB on acute MI remain scarce.  
Based on information from a previous study which discovered that immediate administration 
of ATB effectively prevented the increase in cSNA following a MI (7), in this study I 
hypothesised that ‘delayed’ ATB treatment one hour after the onset of an acute MI would 
effectively reduce sympathetic activation. However, this study was unable to show any 
decrease in cSNA upon administration of ATB as the elevation of cSNA followed that of the 
untreated MI group, therefore indicating that ATB administration one hour after the onset of 
an acute MI does not reduce elevated cSNA levels back to pre-infarct levels. 
Interestingly, although the infarct size for the MI + ATB group (36 ± 4%) was similar to that 
of previous reports, the overall increase in cSNA at four hours was 90 ± 35% which is less than 
expected based on the severity of the infarct which would usually exhibit a larger overall 
increase ranging from 110 – 190% if untreated (7, 40). Possible implications of this finding 
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could be that the actual effect of ATB is underestimated due to differences in infarct size when 
compared with the MI group in this study, or that ATB suppresses the overall increase in cSNA, 
causing the elevated cSNA level to be similar to that of a weaker infarct. However, further 
testing is required to confirm this statement.  
Another possible confounding factor regarding the impact of delayed administration of ATB 
on cSNA relates to the pharmacodynamics of ATB. As a competitive antagonist, ATB targets 
the same OTR binding site as OT (76). Given the one hour delay in ATB administration, it is 
possible that the amount of OT already bound to OTRs in the RVLM, the site of sympathetic 
origin, may be more saturated than if ATB were administered immediately post-MI. This would 
therefore reduce the number of available receptors for ATB to bind to in order to cause an 
inhibitory effect. This possibly suggests that the efficacy of ATB is very much time-reliant, 
and a delay of one hour may be considered too late to cause any significant changes in cSNA.  
 
4.4. Study limitations 
Irregular infarct sizes between study groups 
Despite the fact that all experimental groups were randomised, the infarct sizes of untreated 
MI group in this study were inexplicably but significantly less severe compared to that of the 
MI + ATB group. The probability that all rats which were randomly assigned to the MI group 
would have smaller infarcts is remote, but not impossible. Differences in the severity of infarct 
has been shown to alter electrophysiological and haemodynamic responses, which weakens the 
comparative analysis between study groups (71). This has led to difficulty in accurately 
determining the effect of delayed ATB administration on elevated cSNA. In order to obtain 
similar infarct sizes between groups, additional experiments should be conducted on a larger 
sample size, while focusing on refinement of the LAD coronary occlusion technique.
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Administration of atosiban 
In order to recreate the clinical application as a therapeutic drug, the use of retosiban was 
initially suggested due to its ability to cross the blood brain barrier (BBB) and its intravenous 
administration method. However, I was unable to acquire retosiban due to its sudden 
unavailability and instead selected ATB as a substitute. ATB exhibits mechanisms of action 
similar to that of retosiban and is a suitable substitute for this concept-based study, but is unable 
to be administered intravenously due to its inability to bypass the BBB. In order to rectify this, 
ICV surgery was required to allow for direct administration to the brain. As this method of 
central administration is non-specific, it is not possible to confirm that ATB did not affect other 
oxytocinergic areas of the central nervous system. Furthermore, ATB is not wholly specific to 
OT as compared to retosiban, as it can bind to vasopressin receptors (VPR) as well (77). 
Therefore, if ATB is unable to bind to OTRs, there is a possibility that ATB may bind to VPRs 
instead. Vasopressin is also associated with inhibitory sympathetic regulation (78, 79), which 
may have potentially introduced confounding variables due to the possibility of vasopressin 
inhibition negatively impacting the sympathetic response by preventing sympathetic inhibition.  
To address this issue, immunohistochemical staining can be used to identify the specific neural 
pathways affected by ATB. 
 
Lack of Sham group treated with ATB 
Due to time constraints, the 4th study group ‘Sham + ATB’ was not conducted as part of this 
study. Although this omission may not greatly affect the overall outcome of this study, it 
reduces the ability for meaningful comparison of results between control and treatment groups. 




Direct electrophysiological recordings 
Direct sympathetic nerve recordings have been traditionally used as a reliable approach to 
obtain information regarding changes in SNA in anaesthetized animals from specific 
sympathetic nerves (80). Maintenance of an intact signal for 4 hours required careful nerve 
placement, insulation and constant supervision to prevent nerve displacement or distortion of 
the sympathetic signal from fluid accumulation in the chest cavity. The isolation of the cardiac 
sympathetic nerve was a demanding procedure due to the high risk of nerve damage, thus 
leading to a limited sample size for this study. A steep learning curve was required in order to 
perfect surgical techniques and to minimise operation times. For this reason, a large number of 
rats were excluded from this study based on the fact that the cardiac sympathetic nerve was 
irreparably damaged before the recording protocol had even begun. Despite the difficulty, 
successfully isolated cardiac sympathetic nerves provided an accurate representation of the 
changes occurring in cSNA over time in response to MI and drug treatment which was able to 
be easily compared to previous studies.  
 
Animal models 
The use of murine models have long been used as a means to investigate acute MI and its 
associated mechanisms due to their cardiovascular similarity to humans and easy accessibility, 
maintenance, surgical handling and genetic manipulation (81). Although there are anatomical 
and physiological differences between human and rodent, there are many advantages to a using 
a rat model. It is possible to obtain data from a variety of sympathetic nerves in a rodent body 
via direct nerve recordings, while data collection of sympathetic activity in humans is mostly 
limited to indirect recordings which reduces the accuracy of sympathetic representation (82, 
83). Discrepancies between species is to be expected no matter how physiologically and 
anatomically similar the two groups are, but the use of rodent models have been proven 
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throughout the years to be one of the most appropriate models to use in analysing acute MI 
(81). 
 
Effect of anaesthesia 
The use of anaesthetics is a common limitation due to its potential confounders in cSNA and 
cardiovascular regulation. Commonly used anaesthetics such as barbiturates have been shown 
to depress cardiovascular function and its response to hypothalamic input (84). To circumvent 
these issues, urethane was used in this study to induce surgical anaesthesia. Urethane is 
commonly used as the anaesthetic of choice in animal studies due to it having little to no impact 
on the autonomic and cardiovascular system and its ability to maintain anaesthesia over long 
periods of time, with the physiological parameters being similar to that of an unanaesthetised 
animal (85, 86).  
It was necessary for the administration of anaesthetics due to the highly invasive surgical 
procedures required in this study. As urethane was used, the confounding factors associated 
with changes in autonomic and cardiac regulation was controlled and consistent within all 
groups. Furthermore, consistent doses of urethane was used in each rat, therefore reducing any 
potential confounders associated with drug administration. 
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4.5. Future directions  
The findings from this study gives rise to several factors that would be in need of further 
investigation. A study identifying the efficacy of ATB over time and therefore the optimal 
window of time needed for effective treatment would allow us to determine the applicability 
of ATB as a potential primary response strategy for acute MI.  
Another aspect to examine is the long term benefits/outcomes that could be potentially 
associated with ATB/retosiban treatment, by assessing changes in cSNA, haemodynamics and 
OT levels four weeks after an acute MI. 
Tracking the time course of OT-neuronal activation using fibre photometry during an acute MI 
would also provide further insight into whether neuronal OT activation arises during, or in 
response to an infarct which may shift the perspective of OT-related treatment.  
In this study, male Sprague-Dawley rats were used for experimentation. This was done to 
minimise confounders caused by gender differences and the associated hormonal differences. 
Nonetheless, it is important to determine if ATB’s effect on cardiovascular regulation in 
females is similar to that of males, or if there are any other undiscovered effects to other organs 
in the body that are regulated by OT when used as a treatment for MI, due to ATB’s initial 





To date, medical advancements in developing therapeutic strategies have been successful in 
reducing the mortality risk associated with acute MI. However, primary response strategies 
targeting the increase in cSNA remain an area of active research. This study aimed to explore 
the applicability of ATB as a potential therapeutic drug for acute MI by investigating the 
efficacy of ATB administration one hour post-infarct via in vivo electrophysiological 
recordings of cSNA in a MI rat model. This study was unable to show any significant 
differences in cSNA elevation between the MI and MI + ATB group. Although infarct sizes 
between groups were significantly different, which would affect the validity of comparison 
between groups, the MI + ATB group did not exhibit any decrease in cSNA upon 
administration of ATB at one hour post infarct. One could potentially argue that although ATB 
was not reduced to pre-infarct levels, there is a possibility that ATB may weaken the increase 
in CSNA over time, however further investigation is required to fully elucidate the therapeutic 
potential of ATB. In summary, administration of ATB one hour after a MI did not reduce 
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